SA
ASBP logo
Aspire Biopharma Holdings, Inc.(ASBP)
Closing price · checked 8:16 PM ETAbout this dataData status
$7.13▼-0.52 (-6.80%)
Extended:$7.25+0.12 (+1.68%)· 8:16 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

More ASBP headlines

45 articles

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

accessnewswire.com·Sep 9

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

accessnewswire.com·Sep 8

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

accessnewswire.com·Aug 13

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

accessnewswire.com·Aug 10

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

accessnewswire.com·Jun 24

Aspire Biopharma Stock Is Sliding Today: What's Going On?

benzinga.com·Jun 12

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

accessnewswire.com·Jun 12

Aspire Biopharma Issues Shareholder Letter

accessnewswire.com·May 28

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

accessnewswire.com·May 27

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

accessnewswire.com·May 7

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

accessnewswire.com·Apr 27

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

accessnewswire.com·Apr 20

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

accessnewswire.com·Apr 17

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

accessnewswire.com·Apr 16

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

accessnewswire.com·Apr 15

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

accessnewswire.com·Mar 19

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

accessnewswire.com·Mar 17

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

accessnewswire.com·Mar 12

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

accessnewswire.com·Mar 10

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

accessnewswire.com·Mar 3

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

accessnewswire.com·Feb 25

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

accessnewswire.com·Feb 20

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

accessnewswire.com·Feb 19

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

accessnewswire.com·Feb 17

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

accessnewswire.com·Feb 13

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

accessnewswire.com·Feb 12

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

accessnewswire.com·Feb 11

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

accessnewswire.com·Feb 10

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

accessnewswire.com·Feb 5

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

accessnewswire.com·Feb 3

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

accessnewswire.com·Jan 29

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

accessnewswire.com·Jan 27

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

accessnewswire.com·Jan 22

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

accessnewswire.com·Jan 21

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

accessnewswire.com·Jan 20

Aspire Biopharma Announces Reverse Stock Split

accessnewswire.com·Jan 14

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

accessnewswire.com·Jan 7

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

accessnewswire.com·Dec 18

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

accessnewswire.com·Dec 12

Aspire Biopharma Provides Q3 2025 Business Update

accessnewswire.com·Dec 4

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

accessnewswire.com·Dec 2

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

accessnewswire.com·Nov 26

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

accessnewswire.com·Nov 6

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

accessnewswire.com·Oct 6

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

accessnewswire.com·Oct 3

Latest story Refreshed every 5 minutes; wire stories every 15 minutesAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.